Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04676997
- Locations
- 🇨🇳
Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University Recruiting, Jinan, Shandong, China
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT04668365
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 43
- Registration Number
- NCT04659551
- Locations
- 🇮🇹
Arcispedale S. Anna, Cona, FE, Italy
🇮🇹Azienda Ospedaliera Universitaria di Parma, Parma, PR, Italy
🇮🇹Arcispedale S. Maria Nuova, Reggio Emilia, RE, Italy
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2021-08-12
- Target Recruit Count
- 260
- Registration Number
- NCT04576143
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2020-09-03
- Target Recruit Count
- 55
- Registration Number
- NCT04498793
- Locations
- 🇨🇳
Beijing Huanxing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04433156
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)
- Conditions
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 808
- Registration Number
- NCT04296175
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT04290793
Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- AZ-VUB
- Target Recruit Count
- 63
- Registration Number
- NCT04224922
- Locations
- 🇧🇪
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
🇧🇪Imelda Ziekenhuis, Bonheiden, Belgium
🇧🇪Universitaire Ziekenhuis Antwerpen, Edegem, Belgium
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04214626
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.